Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy
In the TTRACK study, almost one in five patients ≥50 years of age with hypertrophic cardiomyopathy had transthyretin amyloid cardiomyopathy. Greater awareness of the frequency and characteristics of transthyretin amyloid cardiomyopathy in older patients with hypertrophic cardiomyopathy are needed to help improve early detection of this debilitating but treatable disease.
Authors
- Roberto Barriales‐Villa (ORCID: https://orcid.org/0000-0002-6721-3487)
- Perry Elliott (ORCID: https://orcid.org/0000-0003-3383-3984)
- Carmen Munteanu
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Denis Keohane
- Francesco Cappelli (ORCID: https://orcid.org/0000-0002-1622-0732)
- Pablo Mallaina
- Nicolas Piriou (ORCID: https://orcid.org/0000-0002-6677-6552)
- Catherine Bahus
- Thibaud Damy
Institutions
- Inserm (FR)
- Pfizer (United States) (US)
- Université Paris-Est Créteil (FR)
- Universidad Francisco de Vitoria (ES)
- Spanish National Centre for Cardiovascular Research (ES)
- Centro de Investigación en Red en Enfermedades Cardiovasculares (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Centro de Investigación Biomédica en Red (ES)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Complexo Hospitalario Universitario A Coruña (ES)
- Institut du Thorax (FR)
- Institut Mondor de Recherche Biomédicale (FR)
- Instituto de Investigación Biomédica de A Coruña (ES)
- University College London (GB)
- Nantes Université (FR)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1002/ehf2.14971
- Citations
- 22
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 5.14
Funders
- Pfizer